Literature DB >> 32669502

Lymphangioleiomyomatosis Associated with Tuberous Sclerosis Complex.

Keizo Tanitame1.   

Abstract

Entities:  

Keywords:  calcified tuber; lymphangioleiomyomatosis; mammalian target of rapamycin; renal angiomyolipoma; tuberous sclerosis complex

Year:  2020        PMID: 32669502      PMCID: PMC7691031          DOI: 10.2169/internalmedicine.5116-20

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


× No keyword cloud information.
A 31-year-old schizophrenic woman presented to the emergency department with asthma-like dyspnea. Laboratory tests revealed mild anemia, and her room air arterial oxygen saturation by pulse oximetry (SpO2) was 93%. After receiving bronchodilator drugs, her symptoms improved and the SpO2 increased to 98%. A subsequently performed computed tomography scan revealed multiple thin walled cysts and increased pulmonary parenchymal attenuation in the bilateral lungs, subependymal (arrows) and cortical (arrowhead) calcification of the brain, and both kidneys were markedly enlarged with normal tissue being replaced by extensive fat-attenuating tissue (Picture). Lymphangioleiomyomatosis, calcified tubers, and renal angiomyolipomas associated with tuberous sclerosis complex (TSC) were diagnosed based on the Japanese TSC diagnostic criteria. Her forced expiratory volume in 1 second was 2.08 L (76.4% predicted) after bronchodilator administration. Transcatheter arterial embolization to prevent the onset of hemorrhaging from angiomyolipomas (1) was not performed in consideration of the risk of renal function impairment, but instead treatment with a mammalian target of rapamycin inhibitor (2) was initiated.
Picture.
The author states that he has no Conflict of Interest (COI).
  2 in total

1.  Microaneurysms in renal angiomyolipomas: Can clinical and computed tomography features predict their presence and size?

Authors:  J Champagnac; C Melodelima; T Martinelli; G Pagnoux; L Badet; L Juillard; O Rouvière
Journal:  Diagn Interv Imaging       Date:  2016-01-15       Impact factor: 4.026

Review 2.  Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?

Authors:  Samy L Habib; Noor Y Al-Obaidi; Maciej Nowacki; Katarzyna Pietkun; Barbara Zegarska; Tomasz Kloskowski; Wojciech Zegarski; Tomasz Drewa; Edward A Medina; Zhenze Zhao; Sitai Liang
Journal:  J Cancer       Date:  2016-07-21       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.